Why should the Investigator's Brochure be updated?

• A. On a fixed schedule regardless of information
• B. After the trial ends
• C. Only when regulators request it
• D. When significant new safety and efficacy information becomes available

Answer: (D)

The essential point is that the Investigator's Brochure is a living document that must reflect new information that could affect participant safety or how the trial is conducted. When significant new safety or efficacy information becomes available, the IB should be updated so investigators, ethics committees, and sponsor teams have current data to base decisions on. This keeps risk assessments accurate, informs informed consent updates, guides monitoring and management plans, and may trigger protocol or dosing changes if needed.

Why this matters: new adverse events or toxicity signals, new pharmacokinetic or drug interaction data, or any information that shifts the risk-benefit balance can change how subjects are treated, monitored, or consented. Delaying updates means investigators could be operating with outdated assumptions, which undermines subject protection and trial integrity. Updates aren’t on a fixed schedule, nor are they only required after the trial ends or only at regulatory request; they should occur as soon as new, decision-affecting information becomes available.